As the potential threat of biological terrorist attacks continuing to command the attention of governments around the globe, anthrax and smallpox remain amongst the most researched diseases in the biodefense industry.
Anthrax vaccines make up 24% of molecules in the biodefense industry pipeline, while smallpox, despite being eradicated in 1980, accounts for 32% of the total. Viral hemorrhagic fever, a category which amongst others encompasses the Ebola virus, represents 39% of pipeline molecules.
Anthrax and smallpox treatments remain key areas of development due to their high potential for destruction. These diseases can be easily transmitted through the air and have the capacity to inflict widespread devastation if deployed in a bioterrorist attack.
At present, Anthrax Vaccine Adsorbed (AVA) is the only licensed anthrax vaccine, but the use of alternative antimicrobials and antitoxin therapies for anthrax are being researched by the US National Institute of Allergy and Infectious Diseases (NIAID).
Dryvax is the FDA-approved vaccine for smallpox. Approximately 15 million doses of Dryvax vaccine have been stored since production stopped in 1983, however, it is speculated that should there be a biological attack involving smallpox, the available vaccine would not meet the demand. Accordingly, the NIAID has initiated a study to determine the feasibility of diluting Dryvax vaccine to make more doses available from the existing stores.
The US government has allocated more than $50 billion since 2001 to address the threat of biological weapons, with funding for bioweapons-related activities focusing primarily on the research for, and the acquisition of, medicines for defense.
This research report focuses on the key insights into the biodefense industry. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by our team of industry experts. The report provides an in-depth analysis of the biodefense industry. The report examines the bioterrorist events which have resulted in Research and Development (R&D) in the industry. The pharmaceutical countermeasures and treatments by Europe and the US. The report analysis the work of the industry in terms of past, present and future pharmaceutical research, development and production to counter or treat diseases caused by biological attack.
This report is built using data and information sourced from proprietary databases, primary and secondary research, and in house analysis by GBI Research's team of industry experts.
GBI Research also analyzed pipeline of category A pathogens namely, anthrax, small pox, viral hemorrhagic fever, plague and tularemia. Anthrax (24%), smallpox (32%) and viral hemorrhagic fever (39%) contributed a total of 95% of the molecules to the biodefense industry pipeline. Viral hemorrhagic fever, anthrax and small pox are among the most researched diseases in the biodefense industry. It is attributable because of scale of destruction that these two pathogens can cause. According to our analysis, Emergent BioSolutions and SIGA Technologies were awarded a total of 15 contracts between 2007 and 2012.
- Data and analysis on the biodefense industry.
- The competitive landscape of the biodefense industry.
- Key Biodefense Contracts that took place from biodefense industry.
Reasons to buy
- The major trends in R&D in the biodefense industry
- Develop market-entry and market expansion strategies by identifying the potential region and segments poised for strong growth.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Click for Report details:Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans